Mineralys Therapeutics Inc
Research Mineralys Therapeutics Inc (MLYS) on Bullrun: market cap USD 2.17B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMLYS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.17B
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 39.34M
- Free cash flow-USD 39.47M
Valuation Snapshot
latest market cap is USD 2.17B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 154.65M | -USD 142.43M | n/a | -2.29 | USD 172.92M | n/a | USD 646.69M |
| FY2024 | USD 0 | -USD 177.81M | -USD 166.41M | n/a | -3.66 | USD 114.09M | n/a | USD 191.26M |
| FY2023 | n/a | -USD 71.90M | -USD 81.17M | n/a | -1.99 | USD 49.30M | n/a | USD 241.15M |
| FY2022 | n/a | -USD 29.80M | n/a | n/a | -5.77 | USD 87.70M | n/a | -USD 52.27M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.17B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.96B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 613.31M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 353.50M | n/a | n/a | n/a |
About Mineralys Therapeutics Inc
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Mineralys Therapeutics Inc's market cap?
Mineralys Therapeutics Inc's market capitalization is USD 2.17B.
What does Mineralys Therapeutics Inc do?
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc.